Skip to main content

Clinical Criteria Updates (Healthy Blue + Medicare (HMO D-SNP))

Please note, this communication applies to Healthy Blue + Medicare (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).

On December 22, 2022, May 2, 2023, and May 19, 2023, the Pharmacy and Therapeutic (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Blue Cross NC. These policies were developed, revised, or reviewed to support clinical coding edits. 

Visit Clinical Criteria on Anthem.com to search for specific policies. If you have questions or need additional information, email Carelon Healthcare Services.

Please see the explanation / definition for each category of Clinical Criteria below:

  • New: Newly published criteria
  • Revised: Addition or removal of medical necessity requirements, new document number
  • Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other providers in your practice and office staff.

Note:

  • The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services.
  • This notice is meant to inform the provider of new or revised criteria that has been adopted by Blue Cross NC only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective date

Clinical Criteria number

Clinical Criteria title

New or revised

November 1, 2023

*CC-0237

Qalsody (tofersen)

New

November 1, 2023

*CC-0238

Hydroxyprogesterone caproate

New

November 1, 2023

*CC-0240

Zynyz (retifanlimab-dlwr)

New

November 1, 2023

CC-0165

Trodelvy (sacituzumab govitecan)

Revised

November 1, 2023

CC-0002

Colony Stimulating Factor Agents

Revised

November 1, 2023

CC-0128

Tecentriq (atezolizumab)

Revised

November 1, 2023

CC-0098

Doxorubicin Liposome (Doxil, Lipodox)

Revised

November 1, 2023

CC-0101

Torisel (temsirolimus)

Revised

November 1, 2023

CC-0107

Bevacizumab for Non-Ophthalmologic Indications

Revised

November 1, 2023

CC-0143

Polivy (polatuzumab vedotin-piiq)

Revised

November 1, 2023

CC-0092

Adcetris (brentuximab vedotin)

Revised

November 1, 2023

CC-0095

Velcade (bortezomib)

Revised

November 1, 2023

CC-0105

Vectibix (panitumumab)

Revised

November 1, 2023

CC-0178

Synribo (omacetaxine mepesuccinate)

Revised

November 1, 2023

CC-0114

Jevtana (cabazitaxel)

Revised

November 1, 2023

CC-0145

Libtayo (cemiplimab-rwlc)

Revised

November 1, 2023

*CC-0032

Botulinum Toxin

Revised

November 1, 2023

CC-0068

Growth Hormone

Revised

November 1, 2023

*CC-0057

Krystexxa (pegloticase)

Revised

November 1, 2023

*CC-0125

Opdivo (nivolumab)

Revised

November 1, 2023

*CC-0225

Tzield (teplizumab-mzwv)

Revised

November 1, 2023

*CC-0124

Keytruda (pembrolizumab)

Revised

Healthy Blue + Medicare HMO D-SNP

Blue Cross and Blue Shield of North Carolina Senior Health, DBA Blue Cross and Blue Shield of North Carolina, is an HMO D-SNP plan with a Medicare contract and a NC State Medicaid Agency Contract (SMAC). Enrollment in Blue Cross and Blue Shield of North Carolina Senior Health depends upon contract renewal.

NCBCBS-CR-031954-23-CPN30755 July 2023